Get In Touch
Xeraya Capital Sdn Bhd
26.03–26.08, G Tower
#199 Jalan Tun Razak, KL
xeraya@xeraya.com
+603 2381 8700
Submit a Proposal
proposal@xeraya.com
Back

Pharmaceutical Biotech

Rapid Micro Biosystems

Rapid Micro Biosystems is dedicated to providing groundbreaking technology and products to support biomanufacturing companies in their mission to deliver the highest possible quality…

OncoMyx Therapeutics

The myxoma program results from two decades of oncolytic virus research in the laboratory of Professor Grant McFadden. Myxoma is a pox virus that…

Liquidia

Advanced drug particle design Liquidia’s (NASDAQ:LQDA) proprietary nanoparticle (PRINT) technology is a novel fabrication process capable of precisely engineering drug particles to control their…

Imago BioSciences

Imago Biosciences have recently developed inhibitors of the enzyme lysine-specific demethylase 1 (LSD1). This enzyme plays a critical role in regulating the growth and…

Iconic Therapeutics

Treatments for retinal disease and cancer Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines. Iconic has a…

Allecra Therapeutics

To contribute towards the global effort to combat antibiotic resistance Allecra’s contribution is to develop new treatments which overcome emerging resistance mechanisms, thereby saving…

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn Therapeutics is…

Rapid Micro Biosystems

Rapid Micro Biosystems is dedicated to providing groundbreaking technology and products to support biomanufacturing companies in their mission to deliver the highest possible quality…

  • Strategy

    2006

  • Design

    2018

  • Client

    2021 (RPID)

View Project

OncoMyx Therapeutics

The myxoma program results from two decades of oncolytic virus research in the laboratory of Professor Grant McFadden. Myxoma is a pox virus that…

  • Strategy

    2018

  • Design

    2020

View Project

Liquidia

Advanced drug particle design Liquidia’s (NASDAQ:LQDA) proprietary nanoparticle (PRINT) technology is a novel fabrication process capable of precisely engineering drug particles to control their…

  • Strategy

    2004

  • Design

    2017

  • Client

    2018 (LQDA)

View Project

Imago BioSciences

Imago Biosciences have recently developed inhibitors of the enzyme lysine-specific demethylase 1 (LSD1). This enzyme plays a critical role in regulating the growth and…

  • Strategy

    2012

  • Design

    2020

  • Client

    2021 (IMGO)

  • Divested

    2022 (Merck)

View Project

Iconic Therapeutics

Treatments for retinal disease and cancer Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines. Iconic has a…

  • Strategy

    2002

  • Design

    2016

View Project

Allecra Therapeutics

To contribute towards the global effort to combat antibiotic resistance Allecra’s contribution is to develop new treatments which overcome emerging resistance mechanisms, thereby saving…

  • Strategy

    2013

  • Design

    2017

View Project

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn Therapeutics is…

  • Strategy

    2015

  • Design

    2020

  • Client

    2020 (FHTX)

View Project